Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 2(3)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07480356Phase 3Not Yet Recruiting

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Role: lead

NCT06910943Phase 2Recruiting

Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support

Role: lead

NCT05951179Phase 2Recruiting

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Role: lead

NCT05871970Phase 2Recruiting

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Role: lead

NCT05085990Phase 1Completed

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Role: lead

NCT05085977Phase 1Completed

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Role: lead

NCT05011370Completed

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

Role: lead

All 7 trials loaded